Here are three of the vaccine that are tested at the time Moderna's mRNA-1273 Moderna Inc. of Cambridge, Massachusetts, has already begun Phase I human testing of its mRNA-1273 at Kaiser Permanente Washington Health Research Institute in Seattle. The test has enrolled 45 healthy adults ages 18 to 55. Phase I will continue over the next six weeks. Phase I of testing looks at the vaccine's safety and whether it is producing an immune response. A later phase of research will look at whether the vaccine is effective in preventing infection. Inovio's INO-4800 Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania, is using an approach similar to Moderna's to develop a vaccine by modelling off the virus' sequence. Three hours after China published the sequence of the virus online, Inovio developed INO-4800. Inovio uses something called DNA medicine, which is made up of optimized DNA plasmids. Inovio has already developed a vaccine using this